Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism

Background Atrial fibrillation (AF) may exist before or occur early in the course of pulmonary embolism (PE). We determined the PE outcomes based on the presence and timing of AF. Methods and Results Using the data from a multicenter PE registry, we identified 3 groups: (1) those with preexisting AF, (2) patients with new AF within 2 days from acute PE (incident AF), and (3) patients without AF. We assessed the 90‐day and 1‐year risk of mortality and stroke in patients with AF, compared with those without AF (reference group). Among 16 497 patients with PE, 792 had preexisting AF. These patients had increased odds of 90‐day all‐cause (odds ratio [OR], 2.81; 95% CI, 2.33–3.38) and PE‐related mortality (OR, 2.38; 95% CI, 1.37–4.14) and increased 1‐year hazard for ischemic stroke (hazard ratio, 5.48; 95% CI, 3.10–9.69) compared with those without AF. After multivariable adjustment, preexisting AF was associated with significantly increased odds of all‐cause mortality (OR, 1.91; 95% CI, 1.57–2.32) but not PE‐related mortality (OR, 1.50; 95% CI, 0.85–2.66). Among 16 497 patients with PE, 445 developed new incident AF within 2 days of acute PE. Incident AF was associated with increased odds of 90‐day all‐cause (OR, 2.28; 95% CI, 1.75–2.97) and PE‐related (OR, 3.64; 95% CI, 2.01–6.59) mortality but not stroke. Findings were similar in multivariable analyses. Conclusions In patients with acute symptomatic PE, both preexisting AF and incident AF predict adverse clinical outcomes. The type of adverse outcomes may differ depending on the timing of AF onset.

F. Pomero | L. Mazzolai | P. Prandoni | S. Goldhaber | L. Bertoletti | P. Verhamme | F. Moustafa | L. Jara-Palomares | A. Maestre | D. Jiménez | C. Font | G. Vidal | R. Otero | M. Monreal | N. Falvo | G. Lip | A. Muriel | P. Parra | G. Piazza | R. Pesavento | P. Llamas | J. Portillo | J. Caprini | B. Bikdeli | A. Tufano | A. Visoná | A. López-Ruiz | J. I. Arcelus | E. Grau | J. Díez-Sierra | B. Brenner | T. Vanassche | P. Demelo-Rodríguez | R. Maida | H. Bounameaux | I. Weinberg | A. Riera-Mestre | I. Mahé | D. Farge-Bancel | D. Mastroiacovo | M. A. García | S. Roig | C. Ochoa‐Chaar | J. Moisés | P. Di Micco | M. Bosevski | J. Aibar | María Inés Torres | A. Tafur | A. Rivas | F. Uresandi | R. Lopez-reyes | J. Nieto | I. Casado | F. Vázquez | S. Schellong | J. del Toro | L. López‐Jiménez | C. Falgá | A. Skride | L. Font | F. García-Bragado | P. Ruiz-Artacho | J. Lima | A. Ballaz | R. Valle | J. Lobo | I. Tzoran | J. Trujillo-Santos | A. Braester | M. Barrón | J. Ruiz-Ruiz | C. Fernández‐Capitán | R. Malý | R. Barba | J. de Miguel | C. Rodríguez-Matute | R. Quintavalla | P. Debourdeau | C. de Ancos | A. Gil-Díaz | S. Galliazzo | H. Helfer | A. Bura‐Riviere | F. Galeano-Valle | B. Zalunardo | B. Crichi | N. Ait Abdallah | B. Obispo | O. Madridano | P. Marchena | N. Muñoz-Rivas | Á. Blanco‐Molina | R. Sánchez-Martínez | B. Valero | F. Pace | J. díaz-peromingo | J. Suriñach | J. Rogado | M. Ciammaichella | F. Bilora | E. Imbalzano | P. Villares | E. Bucherini | N. Ruíz-Giménez | J. Porras | J. J. López-Núñez | V. Rosa | A. Lorenzo | J. Pedrajas | M. J. Jaras | A. Reis | J. L. Fernández‐Reyes | A. Samperiz | C. Siniscalchi | J. Martín‐Guerra | J. Castro | Manuel Paolo Benjamin Dominique Raquel Pierpaolo Laurent Monreal Prandoni Brenner Farge‐Bancel Barb | H. Bui | M. Adarraga | M. Agud | M. A. Aibar | C. Amado | Carlos Baeza | C. Barbagelata | B. Barrón‐Andrés | E. Botella | A. Camón | I. Cañas | Leyre Chasco | J. Criado | Mario Virgilio Di Campli | I. Domínguez | J. Escribano | A. I. Farfán-Sedano | M. Fidalgo | K. Flores | I. Francisco | C. Gabara | D. Galindo | M. García de Herreros | R. García‐Hernáez | M. García-Mullor | Arantxa García-Raso | O. Gavín‐Sebastián | C. Gómez-Cuervo | Leticia Guirado | J. Gutiérrez | L. Hernández-Blasco | E. Hernando | M. Herreros | R. Jiménez | M. Joya | José Manuel León | P. López-Miguel | J. López-Sáez | M. Martín del Pozo | F. Martín-Martos | C. Mella | M. Mellado | Maria Isabel Mercado | Mª del Valle Morales | A. Muñoz‐Blanco | María Navas | M. Núñez-Fernández | M. Olid | M. C. Olivares | J. L. Orcástegui | Clara Ortega‐Michel | J. Osorio | S. Otalora | Virginia Parra | G. Pellejero | F. Rivera-Cívico | D. Rodríguez-Chiaradía | A. Rodríguez-Cobo | P. Ruiz-Sada | Giorgina Salgueiro | Juan Francisco Sánchez‐Muñoz‐Torrero | T. Sancho | Merçe Sirisi | S. Soler | R. Tirado | C. Tolosa | J. Vela | C. Zamora | P. Gutiérrez | M. Engelen | J. Hirmerová | E. Salgado | E. Olivier | G. Poénou | A. Rocci | R. Romualdi | V. Ģībietis | D. Kigitoviča | Samuel Fonseca | F. Martins | J. Meireles | Hannah Wilkins | D. Jiménez | J. A. Porras | M. Garcia de Herreros | A. Visonà | O. Gavín-Sebastián | A. Muñoz-Blanco | L. López-Jiménez | J. Arcelus | A. Rodríguez-Cobo | A. Bura-Rivière | José Luis Fernández‐Reyes | José María Suriñach | Javier Miguel Martín‐Guerra | Jose Luis Fernández‐Reyes | J. Fernández‐Reyes

[1]  G. Lip,et al.  Understanding the global burden of atrial fibrillation and regional variations: we need improvement. , 2020, Cardiovascular research.

[2]  H. Krumholz,et al.  Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials , 2020, Seminars in Thrombosis and Hemostasis.

[3]  H. Krumholz,et al.  Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research , 2020, Thrombosis and Haemostasis.

[4]  R. Khorasani,et al.  Patient-Level, Institutional, and Temporal Variations in Use of Imaging Modalities to Confirm Pulmonary Embolism , 2020, Circulation. Cardiovascular imaging.

[5]  Yutao Guo,et al.  COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up , 2020, Journal of the American College of Cardiology.

[6]  W. Ageno,et al.  Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database. , 2020, The Lancet. Respiratory medicine.

[7]  D. Jiménez,et al.  Atrial fibrillation in the course of pulmonary embolism: just a little smoke, or fuel to the fire? , 2020, Journal of internal medicine.

[8]  R. Wachter,et al.  Atrial fibrillation is frequent but does not affect risk stratification in pulmonary embolism , 2020, Journal of internal medicine.

[9]  M. Humbert,et al.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) , 2019, European Respiratory Journal.

[10]  H. Krumholz,et al.  Pulmonary Embolism Hospitalization, Readmission, and Mortality Rates in US Older Adults, 1999-2015. , 2019, JAMA.

[11]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association , 2019, Circulation.

[12]  H. Krumholz,et al.  Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE) , 2018, Thrombosis and Haemostasis.

[13]  Deepak L. Bhatt,et al.  Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation , 2017, The New England journal of medicine.

[14]  S. Testa,et al.  Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation. , 2017, The American journal of cardiology.

[15]  G. Lip,et al.  Pulmonary Embolism and Atrial Fibrillation: Two Sides of the Same Coin? A Systematic Review , 2017, Seminars in Thrombosis and Hemostasis.

[16]  Ulrich Schotten,et al.  2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. , 2017, Revista espanola de cardiologia.

[17]  G. Lip,et al.  Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. , 2016, The New England journal of medicine.

[18]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[19]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[20]  L. Kritharides,et al.  The Prevalence and Incidence of Atrial Fibrillation in Patients with Acute Pulmonary Embolism , 2016, PloS one.

[21]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[22]  J. Kline,et al.  Findings From 12-lead Electrocardiography That Predict Circulatory Shock From Pulmonary Embolism: Systematic Review and Meta-analysis. , 2015, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[23]  E. Mathiesen,et al.  Atrial fibrillation and future risk of venous thromboembolism:the Tromsø study , 2015, Journal of thrombosis and haemostasis : JTH.

[24]  F. Sung,et al.  Atrial fibrillation associated with increased risk of venous thromboembolism , 2014, Thrombosis and Haemostasis.

[25]  T. Glotzer,et al.  Silent atrial fibrillation as a stroke risk factor and anticoagulation indication. , 2013, The Canadian journal of cardiology.

[26]  Tom Adriaenssens,et al.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial , 2013, The Lancet.

[27]  T. Perneger,et al.  Is atrial fibrillation associated with pulmonary embolism? , 2012, Journal of thrombosis and haemostasis : JTH.

[28]  O. Dekkers,et al.  Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study , 2011, Journal of thrombosis and haemostasis : JTH.

[29]  Lisa Moores,et al.  Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. , 2010, Archives of internal medicine.

[30]  G. Koraćević,et al.  Is Atrial Fibrillation a Prognosticator in Acute Pulmonary Thromboembolism? , 2010, Medical Principles and Practice.

[31]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[32]  M. Monreal,et al.  Venous thromboembolism in Spain. Comparison between an administrative database and the RIETE registry. , 2008, European journal of internal medicine.

[33]  A. Sueiro,et al.  Valor pronóstico de los hallazgos electrocardiográficos en pacientes estables hemodinámicamente con tromboembolia de pulmón aguda sintomática , 2008 .

[34]  V. Barrios,et al.  [Prognostic value of electrocardiographic findings in hemodynamically stable patients with acute symptomatic pulmonary embolism]. , 2008, Revista espanola de cardiologia.

[35]  Roslyn A Stone,et al.  Derivation and validation of a prognostic model for pulmonary embolism. , 2005, American journal of respiratory and critical care medicine.

[36]  K. Flegel When atrial fibrillation occurs with pulmonary embolism, is it the chicken or the egg? , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.